Simplifying Global Compliance
Pivotal Device Trial Guidance Said to Omit Key Information
Clinical Trials Advisor
Besides lacking key information on confidentiality, a draft guidance seems to imply the FDA prefers randomized studies over other trial designs for pivotal studies of devices pursuing premarket approval and poses impossible barriers for trial manager, according to comments on the document.
To View This Article:
Subscribe To Clinical Trials Advisor
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing